Top Page
Apple
(NASDAQ:AAPL)
Apple (AAPL) vs. SPDR S&P 500 ETF (SPY)
Apple Business Overview & Revenue Model
Apple Key Performance Indicators (KPIs)
Breaks down revenue across different regions, revealing where the company is strongest and where it may face risk or growth potential due to local economic conditions or market share shifts.
Main Street DataApple Earnings Call Summary
Apple Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 416.16B | 416.16B | 391.04B | 383.29B | 260.17B | 265.60B |
| Gross Profit | 195.20B | 195.20B | 180.68B | 169.15B | 98.39B | 101.84B |
| EBITDA | 144.43B | 144.43B | 134.66B | 125.82B | 81.86B | 81.80B |
| Net Income | 112.01B | 112.01B | 93.74B | 97.00B | 55.26B | 59.53B |
Balance Sheet | ||||||
| Total Assets | 359.24B | 359.24B | 364.98B | 352.58B | 338.52B | 365.73B |
| Cash, Cash Equivalents and Short-Term Investments | 54.70B | 54.70B | 65.17B | 61.55B | 100.56B | 66.30B |
| Total Debt | 7.98B | 7.98B | 119.06B | 123.93B | 108.05B | 114.48B |
| Total Liabilities | 285.51B | 285.51B | 308.03B | 290.44B | 248.03B | 258.58B |
| Stockholders Equity | 73.73B | 73.73B | 56.95B | 62.15B | 90.49B | 107.15B |
Cash Flow | ||||||
| Free Cash Flow | 98.77B | 98.77B | 108.81B | 99.58B | 58.90B | 64.12B |
| Operating Cash Flow | 111.48B | 111.48B | 118.25B | 110.54B | 69.39B | 77.43B |
| Investing Cash Flow | 15.20B | 15.20B | 2.94B | 3.71B | 45.90B | 16.07B |
| Financing Cash Flow | -120.69B | -120.69B | -121.98B | -108.49B | -90.98B | -87.88B |
Apple Technical Analysis
Apple Risk Analysis
Apple Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ā | $4.03T | 41.00 | 149.81% | 0.38% | 5.97% | 0.15% | |
| ā | $172.85B | 22.83 | 14.70% | 0.35% | -4.41% | 18.04% | |
| ā | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% | |
| ā | $2.04B | ā | -17.69% | ā | -10.02% | -385.04% | |
| ā | $4.88B | -10.01 | -9.31% | ā | 3.97% | 72.99% | |
| ā | $307.17M | -2.75 | -76.81% | ā | -19.83% | 73.22% | |
| ā | $576.16M | -8.31 | -28.36% | ā | -18.94% | -197.82% |
Apple Corporate Events
Apple Inc., a leader in personal technology and innovation, is renowned for its iPhone, iPad, Mac, and other groundbreaking products and services. The company operates primarily in the technology sector, offering a wide range of hardware and software solutions.
Recent Updates on Apple Inc stock
Apple Inc. (AAPL) recently announced the completion of a clinical study in collaboration with Janssen Scientific Affairs, LLC, titled ‘HEARTLINE – A Heart Health Study Using Digital Technology to Investigate if Early AF Diagnosis Reduces the Risk of Thromboembolic Events Like Stroke IN the Real-world Environment.’ The study, which began in February 2020 and was updated in July 2025, utilized the Apple Watch Series 5 or later to test interventions aimed at improving cardiovascular outcomes and adherence to medication. This development highlights Apple’s commitment to health innovation and may positively influence its stock performance by enhancing investor sentiment as the tech industry increasingly intersects with healthcare.
Recent Updates on Apple Inc stock
Apple Inc. (AAPL) announced the completion of a clinical study in collaboration with Janssen Scientific Affairs, LLC, titled ‘HEARTLINE – A Heart Health Study Using Digital Technology to Investigate if Early AF Diagnosis Reduces the Risk of Thromboembolic Events Like Stroke in the Real-world Environment.’ The study utilized Apple Watch Series 5 or later to test interventions aimed at improving cardiovascular outcomes and adherence to oral anti-coagulants. This development highlights Apple’s commitment to health innovation and could positively influence its stock performance by enhancing investor sentiment as the tech industry increasingly intersects with healthcare.
Recent Updates on Apple Inc stock
Apple Inc. (AAPL) recently completed a clinical study in collaboration with Janssen Scientific Affairs, LLC, titled ‘HEARTLINE – A Heart Health Study Using Digital Technology to Investigate if Early AF Diagnosis Reduces the Risk of Thromboembolic Events Like Stroke IN the Real-world Environment.’ The study, which began in February 2020 and was updated in July 2025, aimed to diagnose Atrial Fibrillation (AF) and improve cardiovascular outcomes using the Apple Watch Series 5 or later. This development highlights Apple’s commitment to health innovation and could positively impact its stock performance by enhancing investor sentiment as the tech industry increasingly intersects with healthcare.
Recent Updates on Apple Inc stock
Apple Inc. (AAPL) recently announced the completion of a clinical study in collaboration with Janssen Scientific Affairs, LLC, titled ‘HEARTLINE – A Heart Health Study Using Digital Technology to Investigate if Early AF Diagnosis Reduces the Risk of Thromboembolic Events Like Stroke IN the Real-world Environment.’ The study, which began on February 25, 2020, and was updated on July 17, 2025, utilized the Apple Watch Series 5 or later to test interventions aimed at improving cardiovascular outcomes. This development highlights Apple’s commitment to health innovation and could positively influence its stock performance by enhancing investor sentiment as the tech industry increasingly intersects with healthcare.
Recent Updates on Apple Inc stock
Apple Inc. (AAPL) recently completed a clinical study in collaboration with Janssen Scientific Affairs, LLC, titled ‘HEARTLINE – A Heart Health Study Using Digital Technology to Investigate if Early AF Diagnosis Reduces the Risk of Thromboembolic Events Like Stroke IN the Real-world Environment.’ The study utilized Apple Watch technology to improve cardiovascular outcomes and adherence to oral anti-coagulants. This development highlights Apple’s commitment to health innovation, potentially boosting investor sentiment and setting a competitive benchmark as the tech industry increasingly intersects with healthcare.
Recent Updates on Apple Inc stock
Apple Inc. (AAPL) has recently completed a clinical study in collaboration with Janssen Scientific Affairs, LLC, titled ‘HEARTLINE – A Heart Health Study Using Digital Technology to Investigate if Early AF Diagnosis Reduces the Risk of Thromboembolic Events Like Stroke IN the Real-world Environment.’ This study, which began in February 2020 and was updated in July 2025, utilized the Apple Watch Series 5 or later to test interventions aimed at improving cardiovascular outcomes. The completion of this study highlights Apple’s commitment to health innovation, potentially enhancing investor sentiment and positively influencing the company’s stock performance as the tech industry increasingly intersects with healthcare.
Recent Updates on Apple Inc stock
Apple Inc. (AAPL) recently announced the completion of a clinical study in collaboration with Janssen Scientific Affairs, LLC, titled ‘HEARTLINE – A Heart Health Study Using Digital Technology to Investigate if Early AF Diagnosis Reduces the Risk of Thromboembolic Events Like Stroke IN the Real-world Environment.’ The study, which began on February 25, 2020, and was updated on July 17, 2025, utilized the Apple Watch Series 5 or later to test interventions aimed at improving cardiovascular outcomes and adherence to anti-coagulants. This development could positively impact Apple’s stock by highlighting the company’s commitment to health innovation and setting a competitive benchmark in the tech-healthcare intersection.
Recent Updates on Apple Inc stock
Apple Inc. (AAPL) recently completed a clinical study in collaboration with Janssen Scientific Affairs, LLC, titled ‘HEARTLINE – A Heart Health Study Using Digital Technology to Investigate if Early AF Diagnosis Reduces the Risk of Thromboembolic Events Like Stroke IN the Real-world Environment.’ The study, which began on February 25, 2020, and was updated on July 17, 2025, tested interventions using the Apple Watch Series 5 or later to improve cardiovascular outcomes and adherence to direct oral anti-coagulants. The completion of this study marks a significant milestone in leveraging digital technology for heart health and could positively influence Apple’s stock performance by enhancing investor sentiment as the tech industry increasingly intersects with healthcare.
Recent Updates on Apple Inc stock
Apple Inc. (AAPL) recently announced the completion of a clinical study in collaboration with Janssen Scientific Affairs, LLC, focusing on heart health using digital technology. The study, titled ‘HEARTLINE,’ aimed to diagnose Atrial Fibrillation (AF) early and improve cardiovascular outcomes through interventions using the Apple Watch Series 5 or later. This development highlights Apple’s commitment to health innovation and could positively influence its stock performance by enhancing investor sentiment as the tech industry increasingly intersects with healthcare.
Recent Updates on Apple Inc stock
Apple Inc. (AAPL) has completed a clinical study in collaboration with Janssen Scientific Affairs, LLC, titled ‘HEARTLINE – A Heart Health Study Using Digital Technology to Investigate if Early AF Diagnosis Reduces the Risk of Thromboembolic Events Like Stroke IN the Real-world Environment.’ This study, which began in February 2020 and was updated in July 2025, tested interventions using the Apple Watch Series 5 or later to improve cardiovascular outcomes and adherence to oral anti-coagulants. The completion of this study highlights Apple’s commitment to health innovation, potentially boosting investor sentiment as the tech industry increasingly intersects with healthcare.
Recent Updates on Apple Inc stock
Apple Inc. (AAPL) recently announced the completion of a clinical study in collaboration with Janssen Scientific Affairs, LLC, titled ‘HEARTLINE – A Heart Health Study Using Digital Technology to Investigate if Early AF Diagnosis Reduces the Risk of Thromboembolic Events Like Stroke IN the Real-world Environment.’ The study, which began on February 25, 2020, and was updated on July 17, 2025, aimed to improve cardiovascular outcomes using the Apple Watch Series 5 or later. This development highlights Apple’s commitment to health innovation, potentially boosting investor sentiment and setting a competitive benchmark as the tech industry increasingly intersects with healthcare.
Recent Updates on Apple Inc stock
Apple Inc. (AAPL) recently announced the completion of a clinical study in collaboration with Janssen Scientific Affairs, LLC, titled ‘HEARTLINE – A Heart Health Study Using Digital Technology to Investigate if Early AF Diagnosis Reduces the Risk of Thromboembolic Events Like Stroke IN the Real-world Environment.’ The study, which began on February 25, 2020, and was updated on July 17, 2025, aimed to identify and diagnose Atrial Fibrillation (AF) and improve cardiovascular outcomes using the Apple Watch Series 5 or later. This development highlights Apple’s commitment to health innovation and could positively influence its stock performance by enhancing investor sentiment as the tech industry increasingly intersects with healthcare.
Recent Updates on Apple Inc stock
Apple Inc. (AAPL) recently announced the completion of a clinical study in collaboration with Janssen Scientific Affairs, LLC, titled ‘HEARTLINE – A Heart Health Study Using Digital Technology to Investigate if Early AF Diagnosis Reduces the Risk of Thromboembolic Events Like Stroke IN the Real-world Environment.’ The study, which began in February 2020 and was updated in July 2025, aimed to diagnose Atrial Fibrillation (AF) and improve cardiovascular outcomes using the Apple Watch Series 5 or later. This development highlights Apple’s commitment to health innovation and could positively influence its stock performance by enhancing investor sentiment as the tech industry increasingly intersects with healthcare.
Recent Updates on Apple Inc stock
Apple Inc. (AAPL) announced the completion of a clinical study in collaboration with Janssen Scientific Affairs, LLC, titled ‘HEARTLINE – A Heart Health Study Using Digital Technology to Investigate if Early AF Diagnosis Reduces the Risk of Thromboembolic Events Like Stroke IN the Real-world Environment.’ The study, which began on February 25, 2020, and was updated on July 17, 2025, tested interventions using the Apple Watch Series 5 or later to improve cardiovascular outcomes and adherence to direct oral anti-coagulants. This development highlights Apple’s commitment to health innovation and could positively influence its stock performance by enhancing investor sentiment as the tech industry increasingly intersects with healthcare.
Recent Updates on Apple Inc stock
Apple Inc. (AAPL) recently announced the completion of a clinical study in collaboration with Janssen Scientific Affairs, LLC, focusing on heart health using digital technology. The study, titled ‘HEARTLINE,’ aimed to diagnose Atrial Fibrillation (AF) early and improve cardiovascular outcomes using the Apple Watch Series 5 or later. Participants were divided into groups based on their AF status and used either an Apple Watch/iPhone or iPhone-only. The study, which began in February 2020 and completed in July 2025, highlights Apple’s commitment to health innovation and could positively impact its stock performance by enhancing investor sentiment as the tech industry increasingly intersects with healthcare.
Recent Updates on Apple Inc stock
Apple Inc. (AAPL) recently announced the completion of a clinical study in collaboration with Janssen Scientific Affairs, LLC, titled ‘HEARTLINE – A Heart Health Study Using Digital Technology to Investigate if Early AF Diagnosis Reduces the Risk of Thromboembolic Events Like Stroke IN the Real-world Environment.’ The study, which began on February 25, 2020, and was updated on July 17, 2025, utilized the Apple Watch Series 5 or later to test interventions aimed at improving cardiovascular outcomes and adherence to oral anti-coagulants. This development highlights Apple’s commitment to health innovation and could positively influence its stock performance by enhancing investor sentiment as the tech industry increasingly intersects with healthcare.
Recent Updates on Apple Inc stock
Apple Inc. (AAPL) has recently completed a clinical study in collaboration with Janssen Scientific Affairs, LLC, titled ‘HEARTLINE – A Heart Health Study Using Digital Technology to Investigate if Early AF Diagnosis Reduces the Risk of Thromboembolic Events Like Stroke IN the Real-world Environment.’ The study, which began on February 25, 2020, and was updated on July 17, 2025, focused on using the Apple Watch Series 5 or later to improve cardiovascular outcomes and adherence to direct oral anti-coagulants. This development highlights Apple’s commitment to health innovation and could positively impact its stock performance by enhancing investor sentiment as the tech industry increasingly intersects with healthcare.
Recent Updates on Apple Inc stock
Apple Inc. (AAPL) has completed a significant clinical study in collaboration with Janssen Scientific Affairs, LLC, titled ‘HEARTLINE – A Heart Health Study Using Digital Technology to Investigate if Early AF Diagnosis Reduces the Risk of Thromboembolic Events Like Stroke IN the Real-world Environment.’ The study, which began in February 2020 and was updated in July 2025, utilized the Apple Watch Series 5 or later to test interventions aimed at improving cardiovascular outcomes and adherence to direct oral anti-coagulants. This development highlights Apple’s commitment to health innovation and could positively influence its stock performance by enhancing investor sentiment as the tech industry increasingly intersects with healthcare.
Recent Updates on Apple Inc stock
Apple Inc. (AAPL) has announced the completion of a clinical study in collaboration with Janssen Scientific Affairs, LLC, titled ‘HEARTLINE – A Heart Health Study Using Digital Technology to Investigate if Early AF Diagnosis Reduces the Risk of Thromboembolic Events Like Stroke IN the Real-world Environment.’ The study, which began in February 2020 and was updated in July 2025, focused on using the Apple Watch Series 5 or later to improve cardiovascular outcomes and adherence to direct oral anti-coagulants. This development highlights Apple’s commitment to health innovation and could positively impact its stock performance by enhancing investor sentiment as the tech industry increasingly intersects with healthcare.
Recent Updates on Apple Inc stock
Apple Inc. (AAPL) recently announced the completion of a clinical study in collaboration with Janssen Scientific Affairs, LLC, titled ‘HEARTLINE – A Heart Health Study Using Digital Technology to Investigate if Early AF Diagnosis Reduces the Risk of Thromboembolic Events Like Stroke IN the Real-world Environment.’ This study, which began in February 2020 and concluded in July 2025, tested interventions using the Apple Watch Series 5 or later to improve cardiovascular outcomes and adherence to oral anti-coagulants. The completion of this study highlights Apple’s commitment to health innovation and could positively influence its stock performance by enhancing investor sentiment as the tech industry increasingly intersects with healthcare.
Recent Updates on Apple Inc stock
Apple Inc. (AAPL) recently completed a clinical study in collaboration with Janssen Scientific Affairs, LLC, titled ‘HEARTLINE – A Heart Health Study Using Digital Technology to Investigate if Early AF Diagnosis Reduces the Risk of Thromboembolic Events Like Stroke IN the Real-world Environment.’ The study, which began on February 25, 2020, and was updated on July 17, 2025, aimed to improve cardiovascular outcomes using the Apple Watch Series 5 or later. This development could positively influence Apple’s stock performance by highlighting the company’s commitment to health innovation, potentially enhancing investor sentiment as the tech industry increasingly intersects with healthcare.
Recent Updates on Apple Inc stock
Apple Inc. (AAPL) has completed a clinical study in collaboration with Janssen Scientific Affairs, LLC, titled ‘HEARTLINE – A Heart Health Study Using Digital Technology to Investigate if Early AF Diagnosis Reduces the Risk of Thromboembolic Events Like Stroke IN the Real-world Environment.’ The study, which began on February 25, 2020, and was updated on July 17, 2025, utilized the Apple Watch Series 5 or later to test interventions aimed at improving cardiovascular outcomes and adherence to oral anti-coagulants. The completion of this study highlights Apple’s commitment to health innovation and could positively influence its stock performance by enhancing investor sentiment as the tech industry increasingly intersects with healthcare.
Recent Updates on Apple Inc stock
Apple Inc. (AAPL) recently announced the completion of a clinical study in collaboration with Janssen Scientific Affairs, LLC, titled ‘HEARTLINE – A Heart Health Study Using Digital Technology to Investigate if Early AF Diagnosis Reduces the Risk of Thromboembolic Events Like Stroke IN the Real-world Environment.’ The study, which utilized the Apple Watch Series 5 or later, aimed to improve cardiovascular outcomes and adherence to direct oral anti-coagulants. This development highlights Apple’s commitment to health innovation and could positively influence its stock performance by enhancing investor sentiment as the tech industry increasingly intersects with healthcare.
Recent Updates on Apple Inc stock
Apple Inc. (AAPL) recently announced the completion of a clinical study in collaboration with Janssen Scientific Affairs, LLC, titled ‘HEARTLINE – A Heart Health Study Using Digital Technology to Investigate if Early AF Diagnosis Reduces the Risk of Thromboembolic Events Like Stroke IN the Real-world Environment.’ This study, which began in February 2020 and was updated in July 2025, aimed to improve cardiovascular outcomes using the Apple Watch Series 5 or later. The completion of this study highlights Apple’s commitment to health innovation and could positively influence its stock performance by enhancing investor sentiment as the tech industry increasingly intersects with healthcare.
Recent Updates on Apple Inc stock
Apple Inc. (AAPL) has announced the completion of a clinical study in collaboration with Janssen Scientific Affairs, LLC, titled ‘HEARTLINE – A Heart Health Study Using Digital Technology to Investigate if Early AF Diagnosis Reduces the Risk of Thromboembolic Events Like Stroke IN the Real-world Environment.’ The study, which began on February 25, 2020, and was updated on July 17, 2025, utilized the Apple Watch Series 5 or later to test interventions aimed at improving cardiovascular outcomes and adherence to oral anti-coagulants. This milestone in digital health innovation could positively impact Apple’s stock by enhancing investor sentiment and setting a competitive benchmark as the tech industry increasingly intersects with healthcare.
Recent Updates on Apple Inc stock
Apple Inc. (AAPL) recently completed a clinical study in collaboration with Janssen Scientific Affairs, LLC, titled ‘HEARTLINE – A Heart Health Study Using Digital Technology to Investigate if Early AF Diagnosis Reduces the Risk of Thromboembolic Events Like Stroke IN the Real-world Environment.’ The study, which began on February 25, 2020, and was updated on July 17, 2025, utilized the Apple Watch Series 5 or later to test interventions aimed at improving cardiovascular outcomes and adherence to direct oral anti-coagulants. This development highlights Apple’s commitment to health innovation and may positively influence its stock performance by enhancing investor sentiment as the tech industry increasingly intersects with healthcare.
Recent Updates on Apple Inc stock
Apple Inc. (AAPL) recently completed a clinical study in collaboration with Janssen Scientific Affairs, LLC, titled ‘HEARTLINE – A Heart Health Study Using Digital Technology to Investigate if Early AF Diagnosis Reduces the Risk of Thromboembolic Events Like Stroke IN the Real-world Environment.’ The study, which began in February 2020 and concluded in July 2025, tested interventions using the Apple Watch Series 5 or later to improve cardiovascular outcomes and adherence to oral anti-coagulants. This development highlights Apple’s commitment to health innovation and could positively influence its stock performance by enhancing investor sentiment as the tech industry increasingly intersects with healthcare.
Apple’s Latest Earnings Call: Record Revenue Amidst Challenges
Apple Inc., a leading technology company renowned for its innovative products and services, operates primarily in the consumer electronics and software industry. Known for its flagship products like the iPhone, iPad, and Mac, Apple continues to set benchmarks in the tech world with its seamless ecosystem of devices and services.
Recent Updates on Apple Inc stock
Apple Inc. (AAPL) recently announced the completion of a collaborative clinical study with Janssen Scientific Affairs, LLC, titled ‘HEARTLINE – A Heart Health Study Using Digital Technology to Investigate if Early AF Diagnosis Reduces the Risk of Thromboembolic Events Like Stroke IN the Real-world Environment.’ This study, which began in February 2020 and was updated in July 2025, utilized the Apple Watch Series 5 or later to test interventions aimed at improving cardiovascular outcomes and adherence to direct oral anti-coagulants. The completion of this study highlights Apple’s commitment to health innovation and could positively influence its stock performance by enhancing investor sentiment as the tech industry increasingly intersects with healthcare.
Recent Updates on Apple Inc stock
Apple Inc (AAPL) recently completed a clinical study in collaboration with Janssen Scientific Affairs, LLC, titled ‘HEARTLINE – A Heart Health Study Using Digital Technology to Investigate if Early AF Diagnosis Reduces the Risk of Thromboembolic Events Like Stroke IN the Real-world Environment.’ The study, which began on February 25, 2020, and was updated on July 17, 2025, utilized the Apple Watch Series 5 or later to test interventions aimed at improving cardiovascular outcomes and adherence to oral anti-coagulants. This completion marks a significant milestone in digital health innovation, potentially enhancing investor sentiment and positively influencing Apple’s stock performance by demonstrating the company’s commitment to health technology.